The UCI has revealed that Chris Froome returned an Adverse Analytical Finding (AAF) at the Vuelta a Espana for twice the permissible dose of the asthma medication Salbutamol. The test took place September 7 following stage 18 of the Vuelta, a race which Froome won overall. Both Froome`s `A` and `B` sample revealed excess Salbutamol. In a statement announcing the AAF, the UCI stated that `the presence of a Specified Substance such as Salbutamol in a sample does not result in the imposition of such mandatory provisional suspension against the rider.` The WADA threshold for Salbutamol is 1,000ng/ml. According to the UCI, Team Sky was notified of the finding on September 20, the day he finished third in the elite men´s time trial at the UCI World Championships in Bergen.ADVERTISEMENT News of the case emerged early on Wednesday morning in Europe after a joint investigation by The Guardian in Britain and Le Monde in France. Froome has previously stated he has suffered from asthma since childhood and has used inhalers in the past. In a statement from the team, Froome explained that his symptoms worsened and he sought medical advice from the team doctor. `My asthma got worse at the Vuelta so I followed the team doctor´s advice to increase my Salbutamol dosage. As always, I took the greatest care to ensure that I did not use more than the permissible dose,` Froome said in a team statement. Chris Froome returns adverse analytical finding for Salbutamol Will Chris Froome`s Salbutamol result sink Team Sky? Vuelta a Espana organisers call for `extreme caution` after Froome Salbutamol result Nibali: Chris Froome Salbutamol case is terrible for the sport The facts on asthma and WADA rules Asthma is a chronic lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Asthma is more common among elite athletes than the general population (70 per cen ...
|
